Entacapone; Tolcapone/Rasagiline; Oral Selegiline
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together at high dosages, your body may not be able to process certain body chemicals (e.g. epinephrine) properly.
What might happen:
You may experience a faster heart rate and/or an increase in blood pressure.
What you should do about this interaction:
Let your your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. At normal dosages, these medicines can be used together. They may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Comtess (entacapone) UK summary of product characteristics. Orion Pharma, UK September 16, 1998.
2.Tasmar (tolcapone) US prescribing information. Valeant Pharmaceuticals International December, 2006.
3.Comtan (entacapone) US prescribing information. Novartis Pharmaceuticals Corporation September, 2010.
4.Comtan (entacapone) Canadian prescribing information. Novartis Pharmaceuticals Canada Inc. March, 2006.
5.Tasmar (tolcapone) UK summary of product characteristics. Valeant Pharmaceuticals Ltd. Januar 11, 2006.
6.Azilect (rasagiline) US prescribing information. Teva Neurosciences Inc. December, 2009.
7.A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005 Feb;62(2):241-8.
8.Eldepryl (selegiline) US prescribing information. Somerset Pharmaceuticals February, 1997.
